Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Selective elimination of alloreactivity in vitro and in vivo while sparing other T-cell-mediated immune responses.

Morecki S, Gelfand Y, Yacovlev E, Eizik O, Shabat Y, Sagiv I, Slavin S.

Bone Marrow Transplant. 2012 Jun;47(6):838-45. doi: 10.1038/bmt.2011.198. Epub 2011 Oct 24.

PMID:
22020024
2.

Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study.

Slavin S, Ackerstein A, Or R, Shapira MY, Gesundheit B, Askenasy N, Morecki S.

Cancer Immunol Immunother. 2010 Oct;59(10):1511-9. doi: 10.1007/s00262-010-0878-1. Epub 2010 Jun 20.

PMID:
20563804
3.

Immunoregulation of GVHD by triggering the innate immune system with CpG.

Morecki S, Slavin S.

Expert Rev Hematol. 2009 Aug;2(4):443-53. doi: 10.1586/ehm.09.29. Review.

PMID:
21082948
4.

Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators.

Morecki S, Yacovlev E, Gelfand Y, Shabat Y, Slavin S.

Biol Blood Marrow Transplant. 2009 Apr;15(4):406-15. doi: 10.1016/j.bbmt.2008.12.504. Epub 2009 Feb 12.

5.

CpG-induced myeloid CD11b+Gr-1+ cells efficiently suppress T cell-mediated immunoreactivity and graft-versus-host disease in a murine model of allogeneic cell therapy.

Morecki S, Gelfand Y, Yacovlev E, Eizik O, Shabat Y, Slavin S.

Biol Blood Marrow Transplant. 2008 Sep;14(9):973-984. doi: 10.1016/j.bbmt.2008.06.018.

6.

Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation.

Prigozhina TB, Khitrin S, Elkin G, Eizik O, Morecki S, Slavin S.

Exp Hematol. 2008 Oct;36(10):1370-6. doi: 10.1016/j.exphem.2008.04.022. Epub 2008 Jul 10.

PMID:
18619727
7.

Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody.

Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Ruf P, Slavin S.

Exp Hematol. 2008 Aug;36(8):997-1003. doi: 10.1016/j.exphem.2008.03.005. Epub 2008 May 20.

PMID:
18495330
8.

Pretransplant treatment of donors with immunomodulators to control graft-versus-host disease (GVHD) in transplant recipients.

Morecki S, Yacovlev E, Gelfand Y, Eizik O, Slavin S.

Exp Hematol. 2007 May;35(5):748-56.

PMID:
17577924
9.

Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes.

Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Slavin S.

Blood. 2006 Feb 15;107(4):1564-9. Epub 2005 Oct 18.

10.

Depletion of alloantigen-primed lymphocytes overcomes resistance to allogeneic bone marrow in mildly conditioned recipients.

Prigozhina TB, Elkin G, Gurevitch O, Morecki S, Yakovlev E, Khitrin S, Slavin S.

Blood Cells Mol Dis. 2004 Nov-Dec;33(3):238-47.

PMID:
15528138
11.

A novel approach for prevention of lethal GVHD by selective elimination of alloreactive donor lymphocytes prior to stem cell transplantation.

Panigrahi S, Morecki S, Yacovlev E, Gelfand Y, Kassir J, Slavin S.

Exp Hematol. 2004 Aug;32(8):756-64.

PMID:
15308327
12.

Effect of KRN7000 on induced graft-vs-host disease.

Morecki S, Panigrahi S, Pizov G, Yacovlev E, Gelfand Y, Eizik O, Slavin S.

Exp Hematol. 2004 Jul;32(7):630-7.

PMID:
15246159
13.

Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy--from bench to patient bedside.

Slavin S, Morecki S, Weiss L, Shapira MY, Resnick I, Or R.

Semin Oncol. 2004 Feb;31(1):4-21. Review.

PMID:
14970932
14.

Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect.

Morecki S, Yacovlev E, Gelfand Y, Vilensky A, Slavin S.

Biol Blood Marrow Transplant. 2004 Jan;10(1):40-8.

15.

Intraportal and systemic allogeneic cell therapy in a murine model of hepatic metastatic breast cancer.

Panigrahi S, Yacovlev E, Gelfand Y, Schuger L, Slavin S, Morecki S.

Cytokines Cell Mol Ther. 2002;7(3):99-106.

PMID:
12850809
16.

Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man.

Slavin S, Morecki S, Weiss L, Or R.

Crit Rev Oncol Hematol. 2003 May;46(2):139-63. Review.

PMID:
12711359
17.
18.

Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.

Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, Morecki S, Andolfi G, Tabucchi A, Carlucci F, Marinello E, Cattaneo F, Vai S, Servida P, Miniero R, Roncarolo MG, Bordignon C.

Science. 2002 Jun 28;296(5577):2410-3.

20.

Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models.

Prigozhina TB, Gurevitch O, Morecki S, Yakovlev E, Elkin G, Slavin S.

Exp Hematol. 2002 Jan;30(1):89-96.

PMID:
11823042
21.
22.

Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen.

Morecki S, Gelfand Y, Nagler A, Or R, Naparstek E, Varadi G, Engelhard D, Akerstein A, Slavin S.

Bone Marrow Transplant. 2001 Aug;28(3):243-9.

23.

Cell Therapy With Preimmunized Effector Cells Mismatched for Minor Histocompatible Antigens in the Treatment of a Murine Mammary Carcinoma.

Morecki S, Yacovlev E, Gelfand Y, Uzi I, Slavin S.

J Immunother (1991). 2001 Mar;24(2):114-121.

PMID:
11449067
24.

Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma.

Morecki S, Yacovlev E, Gelfand Y, Uzi I, Slavin S.

J Immunother. 2001 Mar-Apr;24(2):114-21.

PMID:
11265768
25.

Toward amplification of a graft-versus-leukemia effect while minimizing graft-versus-host disease.

Morecki S, Slavin S.

J Hematother Stem Cell Res. 2000 Jun;9(3):355-66. Review. No abstract available.

PMID:
10894357
26.

Induction of antitumor immunity by indomethacin.

Morecki S, Yacovlev E, Gelfand Y, Trembovler V, Shohami E, Slavin S.

Cancer Immunol Immunother. 2000 Feb;48(11):613-20.

PMID:
10663608
28.

Allogeneic cell therapy for a murine mammary carcinoma.

Morecki S, Yacovlev E, Diab A, Slavin S.

Cancer Res. 1998 Sep 1;58(17):3891-5.

29.

Tumorigenicity and immunogenicity in a murine model of B-cell leukemia/lymphoma (BCL1).

Morecki S, Nagler A, Zakay-Rones Z, Schlesinger M, Lubina-Salomon A, Pugatsch T, Moshel Y, Slavin S.

Leuk Res. 1998 Sep;22(9):831-5.

PMID:
9716015
30.

Cytokine gene transduction into non-immunogeneic murine tumor cells.

Morecki S, Lubina-Salomon A, Slavin S, Nagler A.

Cytokines Cell Mol Ther. 1998 Jun;4(2):87-94.

PMID:
9681247
31.
32.
33.

Activated long-term peripheral blood cultures as preparation for adoptive alloreactive cell therapy in cancer patients.

Morecki S, Gelfand Y, Levi S, Nagler A, Condiotti R, Nabet C, Ackerstein A, Slavin S.

J Hematother. 1997 Apr;6(2):115-24.

PMID:
9131440
34.

Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma.

Morecki S, Moshel Y, Gelfend Y, Pugatsch T, Slavin S.

Int J Cancer. 1997 Mar 28;71(1):59-63.

35.

The effect of linomide, an immunoregulator in experimental autoimmune diseases, on humoral antibody responses in mice.

Morecki S, Nabet C, Falk P, Fridkis-Hareli M, Pecht I, Mond JJ, Slavin S.

Autoimmunity. 1997;25(4):223-32.

PMID:
9344330
36.

Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation.

Kapelushnik J, Nagler A, Or R, Naparstek E, Ackerstein A, Samuel S, Morecki S, Nabet C, Slavin S.

Bone Marrow Transplant. 1996 Dec;18(6):1153-6.

PMID:
8971387
37.

Tumor-cell vaccination induces tumor dormancy in a murine model of B-cell leukemia/lymphoma (BCL1).

Morecki S, Pugatsch T, Levi S, Moshel Y, Slavin S.

Int J Cancer. 1996 Jan 17;65(2):204-8.

38.
39.

Effect of various cytokine combinations on induction of non-MHC-restricted cytotoxicity.

Morecki S, Nagler A, Puyesky Y, Nabet C, Condiotti R, Pick M, Gan S, Slavin S.

Lymphokine Cytokine Res. 1993 Jun;12(3):159-65.

PMID:
8347764
40.

Prevention and treatment of relapse by bone marrow transplantation.

Slavin S, Weiss L, Ackerstein A, Vourka-Karussis U, Morecki S, Or R, Nagler A, Kapelushnik J, Delukina M, Drakos P, et al.

Bone Marrow Transplant. 1993;12 Suppl 3:S54-6. Review.

PMID:
8124259
41.

Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2.

Morecki S, Revel-Vilk S, Nabet C, Pick M, Ackerstein A, Nagler A, Naparstek E, Ben Shahar M, Slavin S.

Cancer Immunol Immunother. 1992;35(6):401-11.

PMID:
1394343
42.

Lymphocytes as cellular vehicles for gene therapy in mouse and man.

Culver K, Cornetta K, Morgan R, Morecki S, Aebersold P, Kasid A, Lotze M, Rosenberg SA, Anderson WF, Blaese RM.

Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3155-9.

43.

The effect of in vitro T lymphocyte depletion on generation of IL2-activated cytotoxic cells.

Morecki S, Nabet C, Ackerstein A, Schlesinger M, Slavin S.

Bone Marrow Transplant. 1991 Apr;7(4):269-73.

PMID:
2070132
44.

Retrovirus-mediated gene transfer into CD4+ and CD8+ human T cell subsets derived from tumor-infiltrating lymphocytes and peripheral blood mononuclear cells.

Morecki S, Karson E, Cornetta K, Kasid A, Aebersold P, Blaese RM, Anderson WF, Rosenberg SA.

Cancer Immunol Immunother. 1991;32(6):342-52.

PMID:
2007247
46.
47.

Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man.

Kasid A, Morecki S, Aebersold P, Cornetta K, Culver K, Freeman S, Director E, Lotze MT, Blaese RM, Anderson WF, et al.

Proc Natl Acad Sci U S A. 1990 Jan;87(1):473-7.

48.

Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia.

Weiss L, Weigensberg M, Morecki S, Bar S, Cobbold S, Waldmann H, Slavin S.

Cancer Immunol Immunother. 1990;31(4):236-42.

PMID:
2379219
49.
50.

Supplemental Content

Loading ...
Support Center